MEA1

Summary

MEA1 (male-enhanced antigen 1, HGNC:6986) is a protein-coding gene on chromosome 6p21.1, encoding Male-enhanced antigen 1 (Q16626). May play an important role in spermatogenesis and/or testis development.

Predicted to be involved in male gonad development and spermatogenesis. Predicted to be located in cytoplasm.

Source: NCBI Gene 4201 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 87 total — 2 pathogenic
• MANE Select transcript: NM_014623

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6986
Approved symbol	MEA1
Name	male-enhanced antigen 1
Location	6p21.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000124733
Ensembl biotype	protein_coding
OMIM	143170
Entrez	4201

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000244711, ENST00000642555, ENST00000642748, ENST00000643776, ENST00000645375, ENST00000645410

RefSeq mRNA: 4 — MANE Select: NM_014623 NM_001318942, NM_001318943, NM_001363578, NM_014623

CCDS: CCDS4879, CCDS87405, CCDS87406

Canonical transcript exons

ENST00000244711 — 4 exons

Exon	Start	End
ENSE00000751517	43012926	43013028
ENSE00000850034	43013115	43013389
ENSE00000850035	43013786	43013946
ENSE00003815401	43011143	43012621

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.3918 / max 199.4382, expressed in 1815 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73655	15.0422	1812
73653	2.4868	1222
73654	0.8043	564
73659	0.0238	3
73656	0.0224	3
73658	0.0123	3

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	99.18	gold quality
right testis	UBERON:0004534	99.11	gold quality
adult organism	UBERON:0007023	98.16	gold quality
testis	UBERON:0000473	98.15	gold quality
sperm	CL:0000019	97.68	gold quality
male germ cell	CL:0000015	97.66	gold quality
parotid gland	UBERON:0001831	97.63	gold quality
prefrontal cortex	UBERON:0000451	97.22	gold quality
cingulate cortex	UBERON:0003027	97.01	gold quality
anterior cingulate cortex	UBERON:0009835	96.97	gold quality
right frontal lobe	UBERON:0002810	96.82	gold quality
amygdala	UBERON:0001876	96.65	gold quality
hypothalamus	UBERON:0001898	96.59	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.50	gold quality
nucleus accumbens	UBERON:0001882	96.45	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.38	gold quality
caudate nucleus	UBERON:0001873	96.37	gold quality
putamen	UBERON:0001874	96.35	gold quality
cranial nerve II	UBERON:0000941	96.31	gold quality
frontal cortex	UBERON:0001870	96.29	gold quality
neocortex	UBERON:0001950	96.26	gold quality
popliteal artery	UBERON:0002250	96.22	gold quality
tibial artery	UBERON:0007610	96.22	gold quality
islet of Langerhans	UBERON:0000006	96.17	gold quality
temporal lobe	UBERON:0001871	96.10	gold quality
aorta	UBERON:0000947	96.04	gold quality
left coronary artery	UBERON:0001626	96.04	gold quality
coronary artery	UBERON:0001621	95.99	gold quality
telencephalon	UBERON:0001893	95.97	gold quality
forebrain	UBERON:0001890	95.96	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	528.58
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

55 targeting MEA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-4271	99.88	68.32	2244
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-8067	99.86	69.59	2260
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-3176	99.25	64.35	954
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-4796-3P	99.08	68.38	1681

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mea1	ENSDARG00000039820
mus_musculus	Mea1	ENSMUSG00000002768
rattus_norvegicus	Mea1	ENSRNOG00000017144
drosophila_melanogaster	CG14341	FBGN0031315

Protein

Protein identifiers

Male-enhanced antigen 1 — Q16626 (reviewed: Q16626)

All UniProt accessions (3): A0A2R8Y6W5, A0A2R8Y7W8, Q16626

UniProt curated annotations — full annotation on UniProt →

Function. May play an important role in spermatogenesis and/or testis development.

Tissue specificity. Highly expressed in testis.

RefSeq proteins (4): NP_001305871, NP_001305872, NP_001350507, NP_055438* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009685	MEA1	Family

Pfam: PF06910

UniProt features (7 total): region of interest 2, compositionally biased region 2, chain 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16626-F1	64.76	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 114

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 164 (showing top): TGCGCANK_UNKNOWN, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_MALE_GAMETE_GENERATION, GGGTGGRR_PAX4_03, GGAMTNNNNNTCCY_UNKNOWN, YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_UP, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, MORF_PPP5C, MORF_FANCG, GRE_C, HIF1_Q3, GATA1_03, GUO_HEX_TARGETS_DN

GO Biological Process (3): spermatogenesis (GO:0007283), male gonad development (GO:0008584), cell differentiation (GO:0030154)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
developmental process involved in reproduction	1
male gamete generation	1
gonad development	1
development of primary male sexual characteristics	1
cellular developmental process	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

804 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MEA1	KLHDC3	Q9BQ90	942
MEA1	PPP2R5D	Q14738	931
MEA1	GOLGA3	Q08378	887
MEA1	SPATA16	Q9BXB7	830
MEA1	KLHL1	Q9NR64	761
MEA1	ZFY	P08048	716
MEA1	ZFX	P17010	649
MEA1	CUL7	Q14999	495
MEA1	KLC4	Q9NSK0	493
MEA1	SFI1	A8K8P3	455
MEA1	PHKG2	P11800	448
MEA1	ZMYND10	O75800	442
MEA1	NUDCD3	Q8IVD9	441
MEA1	SRY	Q05066	437
MEA1	SPATA4	Q8NEY3	435

IntAct

21 interactions, top by confidence:

A	B	Type	Score
IFT25	IFT56	psi-mi:“MI:0914”(association)	0.690
MEA1	AP1M1	psi-mi:“MI:0915”(physical association)	0.670
AP2B1	MEA1	psi-mi:“MI:0915”(physical association)	0.630
ECH1	MCRIP1	psi-mi:“MI:0914”(association)	0.350
ECI2	PDLIM1	psi-mi:“MI:0914”(association)	0.350
ECH1	A2ML1	psi-mi:“MI:0914”(association)	0.350
AP2M1	C1orf226	psi-mi:“MI:0914”(association)	0.350
AP2B1	SYNJ1	psi-mi:“MI:0914”(association)	0.350
MEA1	AP2A1	psi-mi:“MI:0914”(association)	0.350
AP2M1	PER1	psi-mi:“MI:0914”(association)	0.350
AP2B1	AP1G1	psi-mi:“MI:0914”(association)	0.350
AP1M2	AP1G1	psi-mi:“MI:0914”(association)	0.350
MEA1	RAD23A	psi-mi:“MI:0914”(association)	0.350
KRAS	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
AP2M1	CTNND1	psi-mi:“MI:0914”(association)	0.350
AP1M1	MEA1	psi-mi:“MI:0915”(physical association)	0.000
MDM2	MEA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): MEA1 (Affinity Capture-MS), MEA1 (Two-hybrid), MEA1 (Affinity Capture-Western), MEA1 (Affinity Capture-MS), MEA1 (Two-hybrid), MEA1 (Affinity Capture-MS), AP2M1 (Affinity Capture-MS), AP1M1 (Affinity Capture-MS), AP2A1 (Affinity Capture-MS), AP1B1 (Affinity Capture-MS), MEA1 (Affinity Capture-MS), RALGAPB (Affinity Capture-MS), ZER1 (Affinity Capture-MS), ARMCX3 (Affinity Capture-MS), MEA1 (Affinity Capture-MS)

ESM2 similar proteins: A0A804C8T0, A4ZNR4, A4ZNR5, B2RX88, F7C1E2, O00165, O08623, O35387, O70367, O75829, O77770, P17404, P25686, P58340, Q03157, Q08E24, Q13501, Q15773, Q16626, Q29407, Q2KIE2, Q32KY3, Q3UIL6, Q4R992, Q5R491, Q5R4T3, Q5RBA5, Q5XIA0, Q64337, Q6AYN2, Q6BEG7, Q6IQ23, Q6PAQ9, Q7TNY7, Q7TSE9, Q7Z5B4, Q8BK03, Q8BPM6, Q8K3I4, Q8NFW9

Diamond homologs: Q16626, Q29407, Q4R992, Q5FVH7, Q64327, Q95313

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 21 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	6	223.9×	7e-12
The role of Nef in HIV-1 replication and disease pathogenesis	6	223.9×	7e-12
Host Interactions of HIV factors	6	118.5×	4e-10
HIV Infection	6	42.0×	2e-07
MHC class II antigen presentation	6	31.5×	8e-07
Membrane Trafficking	7	15.3×	4e-06
Vesicle-mediated transport	7	14.3×	5e-06
Viral Infection Pathways	6	10.9×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
synaptic vesicle endocytosis	5	113.7×	1e-07
vesicle-mediated transport	6	30.4×	3e-06
intracellular protein transport	6	20.5×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	56
Likely benign	18
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
190286	NM_006245.4(PPP2R5D):c.592G>A (p.Glu198Lys)	Pathogenic
2422814	NC_000006.11:g.(?41126341)(43752536_?)del	Pathogenic

SpliceAI

807 predictions. Top by Δscore:

Variant	Effect	Δscore
6:43011143:A:AG	acceptor_gain	1.0000
6:43011144:C:G	acceptor_gain	1.0000
6:43011144:CACA:C	acceptor_loss	1.0000
6:43011145:A:AG	acceptor_gain	1.0000
6:43011146:C:G	acceptor_gain	1.0000
6:43011147:A:AG	acceptor_gain	1.0000
6:43011147:AGA:A	acceptor_loss	1.0000
6:43011147:AGAT:A	acceptor_gain	1.0000
6:43011148:G:GA	acceptor_gain	1.0000
6:43011148:GA:G	acceptor_gain	1.0000
6:43011148:GAT:G	acceptor_gain	1.0000
6:43011148:GATG:G	acceptor_gain	1.0000
6:43011148:GATGC:G	acceptor_gain	1.0000
6:43012920:TTTTA:T	donor_loss	1.0000
6:43012921:TTTA:T	donor_loss	1.0000
6:43012922:TTAC:T	donor_loss	1.0000
6:43012923:TA:T	donor_loss	1.0000
6:43012924:A:T	donor_loss	1.0000
6:43012925:C:CA	donor_loss	1.0000
6:43013029:C:CC	acceptor_gain	1.0000
6:43013030:T:A	acceptor_loss	1.0000
6:43013109:CCCTA:C	donor_loss	1.0000
6:43013110:CCTA:C	donor_loss	1.0000
6:43013111:CTACC:C	donor_loss	1.0000
6:43013112:TA:T	donor_loss	1.0000
6:43013114:CCTG:C	donor_loss	1.0000
6:43013125:T:TA	donor_gain	1.0000
6:43013176:T:TA	donor_gain	1.0000
6:43012618:TGTT:T	acceptor_gain	0.9900
6:43012622:C:CC	acceptor_gain	0.9900

AlphaMissense

1197 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:43012527:C:A	W167C	0.999
6:43012527:C:G	W167C	0.999
6:43012529:A:G	W167R	0.999
6:43012529:A:T	W167R	0.999
6:43012554:C:A	W158C	0.999
6:43012554:C:G	W158C	0.999
6:43012556:A:G	W158R	0.999
6:43012556:A:T	W158R	0.999
6:43012528:C:G	W167S	0.998
6:43012602:T:A	K142N	0.997
6:43012602:T:G	K142N	0.997
6:43012606:A:T	V141E	0.997
6:43013210:A:G	Y70H	0.997
6:43012552:G:T	A159D	0.996
6:43012594:A:G	M145T	0.996
6:43012609:A:G	L140P	0.996
6:43013018:A:G	L105P	0.996
6:43013012:A:G	L107S	0.995
6:43013018:A:T	L105H	0.995
6:43012555:C:G	W158S	0.994
6:43012593:C:A	M145I	0.994
6:43012593:C:G	M145I	0.994
6:43012593:C:T	M145I	0.994
6:43012594:A:C	M145R	0.994
6:43013210:A:C	Y70D	0.994
6:43012594:A:T	M145K	0.993
6:43013210:A:T	Y70N	0.992
6:43012933:C:A	M133I	0.991
6:43012933:C:G	M133I	0.991
6:43012933:C:T	M133I	0.991

dbSNP variants (sampled 300 via entrez): RS1000201066 (6:43015228 C>T), RS1001039061 (6:43013797 T>A), RS1001151588 (6:43013978 A>C,G), RS1001268356 (6:43014282 C>T), RS1002256055 (6:43017173 T>C), RS1003230003 (6:43015408 AG>A), RS1003259398 (6:43015942 T>TG), RS1003560736 (6:43016394 T>G), RS1003570995 (6:43011096 G>A,C,T), RS1003611761 (6:43016047 T>A), RS1005103724 (6:43016740 G>C), RS1005567443 (6:43016504 A>G), RS1005910290 (6:43012020 G>C), RS1006522764 (6:43018539 G>A), RS1006854541 (6:43014883 A>G)

Disease associations

OMIM: gene MIM:143170 | disease phenotypes: MIM:616355, MIM:214100

GenCC curated gene-disease

Mondo (3): Houge-Janssens syndrome 1 (MONDO:0014602), intellectual disability (MONDO:0001071), peroxisome biogenesis disorder (MONDO:0019234)

Orphanet (3): Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome (Orphanet:457279), Peroxisome biogenesis disorder (Orphanet:79189), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
C536664	Peroxisome biogenesis disorders (supp.)
C531857	Zellweger leukodystrophy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
manganese chloride	increases abundance, increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Atrazine	increases expression	1
Coumestrol	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	increases abundance, increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	increases oxidation, increases abundance, affects cotreatment	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3AY	Abcam HEK293T MEA1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT01838941	PHASE3	COMPLETED	Betaine and Peroxisome Biogenesis Disorders
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT03856866	PHASE2	COMPLETED	Hydroxychloroquine Administration for Reduction of Pexophagy
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1